{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:02:29Z","timestamp":1767139349601,"version":"build-2238731810"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n COVID-19 as a pandemic calls for rapid development of vaccines.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Here a proposal of a seamless, adaptive, phase 1\u20133 trial for accelerated vaccine development is described.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2\u00a0weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16\u00a0weeks, general vaccination would be feasible if supply meets the demand.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00228-020-02933-w","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T18:02:41Z","timestamp":1592330561000},"page":"1471-1472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calling for an exponential escalation scheme in vaccine development for COVID-19"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-1691","authenticated-orcid":false,"given":"Martin","family":"Wehling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"2933_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/d41586-020-00927-3","volume":"580","author":"E Callaway","year":"2020","unstructured":"Callaway E (2020) Should scientists infect healthy people with the coronavirus to test vaccines? Nature 580:17","journal-title":"Nature"},{"key":"2933_CR2","volume-title":"Principles of translational science in medicine - from bench to bedside","author":"M Wehling","year":"2015","unstructured":"Wehling M (2015) Principles of translational science in medicine - from bench to bedside, 2nd edn. Academic Press, Waltham","edition":"2"},{"key":"2933_CR3","doi-asserted-by":"publisher","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","volume":"7","author":"SS Ahmed","year":"2015","unstructured":"Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A et al (2015) Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 7:294ra105","journal-title":"Sci Transl Med"}],"updated-by":[{"DOI":"10.1007\/s00228-021-03165-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02933-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02933-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T07:47:32Z","timestamp":1633420052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02933-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":3,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2933"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02933-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00228-021-03165-2","URL":"https:\/\/doi.org\/10.1007\/s00228-021-03165-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}